Abstract
Triple negative breast cancer is known for its visceral metastasis. We have found that CXCR4 is overexpressed in triple negative breast cancer and is associated with visceral metastasis. We further investigated whether CXCR4 is a prognostic factor affecting survival following visceral metastasis in breast cancer patients. Our results indicate that increased CXCR4 expression among breast cancer patients with visceral metastasis was positively correlated with poor overall survival (P<0.001). Silencing of CXCR4 was associated with a decrease in the tumorigenic properties of MDA-MB-231 breast cancer cells, caused reversion of EMT and suppression of MMP-9, increased apoptosis, and caused a reduced incidence of tumor lung metastasis in mice. These results are indicative of CXCR4 having a predictive role in patients with visceral metastasis and indicate that shRNA knock down of CXCR4 might be a novel therapeutic strategy to prevent breast cancer metastasis when CXCR4 is overexpressed.
Keywords: Apoptosis, chemokine (C-X-C motif) ligand 12 (CXCL12), CXC chemokine receptor types 4 (CXCR4), EMT (epithelial mesenchymal transition), shRNA, triple negative breast cancer, visceral organ specific metastases.
Current Molecular Medicine
Title:Aberrant Expression of CXCR4 Significantly Contributes to Metastasis and Predicts Poor Clinical Outcome in Breast Cancer
Volume: 14 Issue: 1
Author(s): P. Yang, S.-X. Liang, W.-H. Huang, H.-W. Zhang, X.-L. Li, L.-H. Xie, C.-W. Du and G.-J. Zhang
Affiliation:
Keywords: Apoptosis, chemokine (C-X-C motif) ligand 12 (CXCL12), CXC chemokine receptor types 4 (CXCR4), EMT (epithelial mesenchymal transition), shRNA, triple negative breast cancer, visceral organ specific metastases.
Abstract: Triple negative breast cancer is known for its visceral metastasis. We have found that CXCR4 is overexpressed in triple negative breast cancer and is associated with visceral metastasis. We further investigated whether CXCR4 is a prognostic factor affecting survival following visceral metastasis in breast cancer patients. Our results indicate that increased CXCR4 expression among breast cancer patients with visceral metastasis was positively correlated with poor overall survival (P<0.001). Silencing of CXCR4 was associated with a decrease in the tumorigenic properties of MDA-MB-231 breast cancer cells, caused reversion of EMT and suppression of MMP-9, increased apoptosis, and caused a reduced incidence of tumor lung metastasis in mice. These results are indicative of CXCR4 having a predictive role in patients with visceral metastasis and indicate that shRNA knock down of CXCR4 might be a novel therapeutic strategy to prevent breast cancer metastasis when CXCR4 is overexpressed.
Export Options
About this article
Cite this article as:
Yang P., Liang S.-X., Huang W.-H., Zhang H.-W., Li X.-L., Xie L.-H., Du C.-W. and Zhang G.-J., Aberrant Expression of CXCR4 Significantly Contributes to Metastasis and Predicts Poor Clinical Outcome in Breast Cancer, Current Molecular Medicine 2014; 14 (1) . https://dx.doi.org/10.2174/1566524013666131121115656
DOI https://dx.doi.org/10.2174/1566524013666131121115656 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Perspectives on Medicinal Properties of Mangiferin
Mini-Reviews in Medicinal Chemistry The Role of a Human Hematopoietic Mesenchymal Progenitor in Wound Healing and Fibrotic Diseases and Implications for Therapy
Current Stem Cell Research & Therapy FDG-PET/CT for Systemic Infections
Current Molecular Imaging (Discontinued) Non-Analgesic Effects of Opioids: The Cognitive Effects of Opioids in Chronic Pain of Malignant and Non-Malignant Origin. An Update.
Current Pharmaceutical Design Novel VEGF-independent Strategies Targeting Tumor Vasculature: Clinical Aspects
Current Pharmaceutical Design Dual Role of S100A8 and S100A9 in Inflammation-Associated Cancer
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Discovery of Lansoprazole and its Unique Pharmacological Properties Independent from Anti-secretory Activity
Current Pharmaceutical Design Chemotherapy and Delivery in the Treatment of Primary Brain Tumors
Current Clinical Pharmacology Recent Advances of Poly(ether-ether) and Poly(ether-ester) Block Copolymers in Biomedical Applications
Current Drug Metabolism Cancer Stem Cells – Are Surface Markers Alone Sufficient?
Current Stem Cell Research & Therapy MT1-MMP Activation of TGF-β Signaling Enables Intercellular Activation of an Epithelial-mesenchymal Transition Program in Cancer
Current Cancer Drug Targets Anticancer Drugs Discovery and Development from Marine Organisms
Current Topics in Medicinal Chemistry Current Advances in the Synthesis and Biological Evaluation of Pharmacologically Relevant 1,2,4,5-Tetrasubstituted-1H-Imidazole Derivatives
Current Organic Chemistry Prevention of Colitis-associated Cancer: Natural Compounds that Target the IL-6 Soluble Receptor
Anti-Cancer Agents in Medicinal Chemistry Chemically Functionalized Carbon Nanotubes: Emerging Vectors for Cell Therapy
Mini-Reviews in Medicinal Chemistry Telomerase Inhibitors: Potential Anticancer Agents
Mini-Reviews in Organic Chemistry Application of dsRNA in Cancer Immunotherapy: Current Status and Future Trends
Anti-Cancer Agents in Medicinal Chemistry Novel Molecular Anti- Colorectalcancer Conjugate:Chlorambucil-Adipic Acid Dihydrizide-Glutamine
Anti-Cancer Agents in Medicinal Chemistry Strategies for the Assessment of Metabolic Profiles of Steroid Hormones in View of Diagnostics and Drug Monitoring: Analytical Problems and Challenges
Current Drug Metabolism A Neural Network-Based QSAR Approach for Exploration of Diverse Multi-Tyrosine Kinase Inhibitors and its Comparison with a Fragment- Based Approach
Current Computer-Aided Drug Design